Children with newly diagnosed immune thrombocytopenia (ITP) treated with eltrombopag as a frontline therapy show significantly improved platelet responses and other outcomes compared with the standard ...

Rilzabrutinib (Wayrilz; Sanofi), a BTK inhibitor, targets immune-mediated platelet destruction in immune thrombocytopenia (ITP) and has demonstrated a favorable safety profile.

An expert discusses how rilzabrutinib uniquely improves quality-of-life metrics, including fatigue and women’s health domains, which previous immune thrombocytopenia (ITP) therapies failed to address ...

SAN DIEGO -- Treatment with an investigational oral inhibitor of Bruton's tyrosine kinase (BTK) was safe and boosted platelet counts in heavily pretreated patients with immune thrombocytopenia (ITP), ...

Thrombosis risk is elevated in patients with immune thrombocytopenia (ITP), and the results of a recent study suggest that it is a separate indication for anticoagulation, particularly following ...

Immune thrombocytopenia (ITP) is a rare blood disorder in which the immune system mistakenly attacks and destroys platelets. Platelets are small blood cells that play a critical role in helping your ...

(SAN FRANCISCO, December 6, 2008) – Four studies that highlight significant advances in treatment and survival outcomes for patients with various forms of thrombocytopenia, a group of bleeding ...

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia (ITP), an autoimmune ...

Most experts would treat you for one to two weeks, then taper the medicine off over a few weeks. The side effects of this dose of steroids are modest if it does not need to be frequently repeated.

Sanofi ($SNYNF) announced an update on their ongoing clinical study. Study Overview Sanofi has completed an observational study titled “Cognitive ...

Immune thrombocytopenia (ITP) is a rare condition that causes a low platelet count. People with ITP can experience life threatening bleeding if the condition is not treated. Many people with ITP go ...

In a large multicenter cohort, dual antiplatelet therapy showed the greatest 90 day benefit when started within 24 hours ...